This meta-regression analysis, using the digitalized individual information on time to death from ten large CVOTs on DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors, including 99,746 observations and 7563 deaths, showed no evidence for the potential of the precision treatment approach in type 2 diabetes with respect to all-cause mortality. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.